Vaccine News and Research

Latest Vaccine News and Research

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company is set to be added to the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions updated on June 18 on www.russell.com.

21 Jun 2010

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.

21 Jun 2010

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Children exposed to polychlorinated biphenyls early in life later had a diminished immune response to diphtheria and tetanus vaccinations, according to a study published online June 20 ahead of print in the peer-reviewed journal Environmental Health Perspectives. This result suggests that PCB exposure during the first years of life, a critical period in immune system development, could undermine the effectiveness of childhood vaccinations and possibly impair immune system responses to infection.

21 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Recent releases in Global Health

The U.N.'s plan to improve maternal health is lacking "the one element that will make it work. Human rights," according to blog post on Huffington Post. "Medical causes of maternal death - hemorrhage, sepsis, hypertension, unsafe abortion, HIV and AIDS - are inextricably linked to human rights. Each one of these instances can be prevented or treated by simply respecting women's human rights in health policies and delivery of services, and addressing systemic gender inequality."

19 Jun 2010

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Children's Hospital Boston announced today that it has received a $2.4 million grant from the Bill & Melinda Gates Foundation. The grant will support the development of novel vaccines for newborns – research that is spearheaded by Ofer Levy, MD, Ph.D., a principal investigator in the Division of Infectious Diseases at Children's.

18 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

MicroStockProfit releases investment report on Oncothyreon

MicroStockProfit.com announces an investment report featuring Oncothyreon Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

18 Jun 2010

New polio strategy builds on 99% drop in Nigeria cases but faces 50% funding shortfall

In Geneva this Friday, a broad range of stakeholders will formally launch the new Strategic Plan 2010-2012 for eradicating wild poliovirus.

18 Jun 2010

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.

18 Jun 2010

Drug makers face tightened regulations by FDA and less clout at medical meetings

The Washington Post: "The Food and Drug Administration this week began posting online the results of safety evaluations of recently approved drugs and vaccines. The action follows a law enacted in 2007 that requires the agency to provide more safety information to consumers and health professionals. The evaluations must be conducted 18 months after a new drug comes on the market.

18 Jun 2010

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

Mice injected with a 2009 H1N1 pandemic influenza vaccine and then exposed to high levels of the virus responsible for the 1918 influenza pandemic do not get sick or die, report scientists funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

17 Jun 2010

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.

17 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

Experimental vaccine for Marburg hemorrhagic fever prevention shows promise for accidental exposures

An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate.

17 Jun 2010

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

A team of molecular biologists and computer scientists at Stony Brook University have used a novel method to weaken (attenuate) influenza virus by way of designing hundreds of mutations to its genetic code to create an effective vaccine. Reported online and in the July issue of Nature Biotechnology, the method may be a major step in developing more effective and safe vaccines against influenza, which claims 250,000 to 500,000 lives annually worldwide, partly because existing vaccines are not fully effective.

17 Jun 2010

Stimuvax clinical program resumed in patients with NSCLC

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that they are resuming their Stimuvax (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer which includes the Phase III studies, START and INSPIRE. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

SAHM strongly recommends HPV vaccines for males

Recent releases in Global Health

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

BioSante announces presentation of LibiGel safety update at ENDO 2010

MicroStockProfit releases investment report on Oncothyreon

New polio strategy builds on 99% drop in Nigeria cases but faces 50% funding shortfall

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Drug makers face tightened regulations by FDA and less clout at medical meetings

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

Scientific American publishes article on "rebirth" of DNA vaccines

CINJ researchers combine series of vaccination injections to treat prostate cancer

Experimental vaccine for Marburg hemorrhagic fever prevention shows promise for accidental exposures

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

Stimuvax clinical program resumed in patients with NSCLC

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in